AbbVie: Q4 Earnings Insights

Shares of AbbVie ABBV rose 1.1% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 32.13% over the past year to $2.92, which beat the estimate of $2.85.

Revenue of $13,858,000,000 up by 59.21% from the same period last year, which beat the estimate of $13,700,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $12.32 and $12.52.

Details Of The Call

Date: Feb 03, 2021

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/hde6n23s

Price Action

52-week high: $113.41

52-week low: $62.55

Price action over last quarter: Up 18.30%

Company Overview

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.